Solid find. Just a quick question- how do they split profits with PAR pharma if this gets to market? This announcement just mentions a royalty if it gets to market. Under the terms of the agreement, Optimer will fund all expenses associated with the clinical trials of PAR-101. Par will be responsible for clinical development, and, if successful, Par will submit the New Drug Application for the product. All legal and regulatory responsibilities also reside with Par. If ultimately cleared for marketing, Par will manufacture and market PAR-101. Par has exclusive rights to market, sell and distribute the product in the U.S. and Canada. Par will pay Optimer a royalty on sales of the product. Par has an option to extend the joint development and collaboration agreement to include up to three additional drug candidates from Optimer's pipeline. http://www.parpharm.com/media/NR_20050503.jspWhere do I look for more details? Into the SEC filings?BTW, this is making me like one of my other potential picks for the contest even better - since it recently got its european marketing rights back from a partner. Hmmm...thinking...Sarah
Best Of |
Favorites & Replies |
Start a New Board |
My Fool |
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar<